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ABSTRACT
The benefit of adding chemotherapy (CT) to adjuvant hormone therapy (HT) in 
stage IA luminal-like HER2-negative breast cancer (BC) is unclear. We retrospectively 
evaluated predictive factors and clinical outcome of 1,222 patients from 4 oncologic 
centers. Three hundred and eighty patients received CT and HT (CT-cohort) and 
842 received HT alone (HT-cohort). Disease-free survival (DFS) and overall survival 
(OS) were evaluated with univariate and multivariate analyses. We also applied the 
propensity score methodology. Compared with the HT-cohort, patients in the CT-cohort 
were more likely to be younger, have larger tumors of a higher histological grade that 
were Ki67-positive, and lower estrogen and progesterone receptor expression. At 
univariate analysis, a higher histological grade and Ki67 were significantly associated 
to a lower DFS. At multivariable analysis, only histological grade was predictive of 
DFS. The CT-cohort had a worse outcome than the HT-cohort in terms of DFS and 
OS, but differences disappeared when matched according to propensity score. In 
summary, patients with stage IA luminal-like BC had an excellent prognosis, however 
relapse and mortality were higher in the CT-cohort than in the HT-cohort. Longer use 
of adjuvant HT or other therapeutic strategies may be needed to improve outcome.
INTRODUCTION
Implementation of screening programs has increased 
the diagnosis of early stage breast cancers in westernized 
countries [1-6]. Among these cases, tumors measuring 
≤2 cm without lymph node involvement (N0), classified 
as stage IA breast cancer [7], generally have a low rate 
of metastatic relapse and a favorable outcome [4, 8-13]. 
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Adjuvant hormonal treatment (HT) is the main therapeutic 
option for patients with stage IA “luminal-like HER2-
negative” disease (“luminal-like breast cancer”), which is 
defined by the expression of hormone receptors (HR) and 
the absence of HER2 overexpression and/or amplification 
[14]. Clinical and tumoral features can help to characterize 
risk and select which patients may need CT in addition to 
HT. However, parameters such as tumor size and nodal 
status may not completely reflect the wide molecular 
heterogeneity seen among breast tumors even within the 
HR–positive subgroup [15]. Multigene prognostic tools 
are now beginning to guide treatment decision making. 
Of these, the Recurrence Score (RS) generated by the 
Oncotype DX® assay (Genomic Health, Redwood City, 
CA) gives a validated estimate of prognosis for patients 
with N0, estrogen receptor (ER)–positive disease if treated 
with tamoxifen alone [16, 17]. However, genomic tests are 
not always available in clinical practice, and conventional 
tumoral and clinical parameters still play a critical role in 
disease management and are the most popular tools for 
risk stratification in this setting. Importantly, irrespective 
of the criteria chosen for risk stratification, the amount of 
benefit associated with the addition of CT to HT is unclear.
The aim of this study was to evaluate the clinical 
outcome of a large cohort of patients affected by luminal-
like stage IA breast cancer who received adjuvant HT with 
or without CT, and the prognostic value of patient- and 
tumor-related markers.
RESULTS
Population demographics and pathological 
features
A total of 1,222 patients from 4 Italian Oncologic 
Centers with luminal-like stage IA breast cancer who 
underwent surgery between 1996 and 2012 were 
identified. Data on tumor size, histological grade, ER 
and PgR status and Ki67 were available for 97% (1191), 
96% (1,170), 99% (1,208), 98% (1,201) and 86% (1,049) 
of patients, respectively. The median age at the time of 
breast cancer diagnosis was 57 years (range:26-88 years; 
interquartile range, from 48 to 65 years) and 7% (87) 
of cases were classified T1a, 32% (381) T1b, and 61% 
(723) T1c. All patients included in this study had received 
adjuvant systemic therapy. In detail, 69% of patients 
(842) were treated with HT alone, and 31% (380) with CT 
followed by HT. The distribution of the adjuvant systemic 
treatments delivered in the different Oncologic Centers 
where patients were treated are shown in Supplementary 
Table 1. Seventy-eight percent (909) of tumors had a low-
moderate (G1-G2) histological grade, 65% (687) had a low 
proliferation rate evaluated with a Ki67 threshold of 20%, 
and 52% (544) had a low ki67 evaluated using a threshold 
of 14%. With respect to HR levels, 99% (1,208) of tumors 
were ER-positive, with a median ER positivity of 80% 
(range 0-100%), and 91% (1,111) were PgR-positive, with 
a median PgR positivity of 70% (range 0-100%). Among 
PgR-positive tumors, 81% (965) had high levels of PgR 
(PgR≥20%).
The distribution of the demographic and pathologic 
characteristics of the CT vs HT cohort of patients is 
reported in Table 1. Age, tumor size, tumor grade, Ki67, 
ER and PgR expression differed significantly between 
the two cohorts. Patients in the CT cohort compared to 
those in the HT-cohort were more likely to be younger 
(median age 50 vs 61 years; p<0.001, respectively), and 
to have a larger tumor (T1c rates 81%vs. 52%; p<0.001, 
respectively) that had a higher histological grade (G3 rates 
47% vs 12%; p<0.001, respectively), lower ER and PgR 
expression (ER positivity rate 96% vs 100%; p<0.001; 
median levels of ER expression 70% vs 90%; p<0.001; 
median PgR levels 50% vs 70%; p<0.001, respectively) 
and a higher proliferation index for both Ki67 cut-offs 
(Ki67 >20% 56% vs 25%; p<0.001, and Ki67 >14% 68% 
vs 40%; p<0.001, respectively). Not surprisingly given the 
distribution of baseline characteristics, the rates of luminal 
A breast cancer were 23% vs 48% and the rates of luminal 
B breast cancer were 77% vs 52% in the CT-cohort vs the 
HT-cohort, respectively (p<0.001).
Information about chemotherapy regimen was 
available for 99% of patients in the CT cohort. In detail, 
58% (219) of patients received anthracycline-containing 
only regimens, 16% (60) received regimens based on both 
anthracyclines and taxanes, 2% (8) received a taxane-
based only regimen, and 23% (89) received neither 
anthracycline- nor taxane-containing chemotherapy 
(Supplementary Table 2).
Survival outcomes
Overall, with a median follow-up of 8.3 years 
(range: 1 to 16.4 years) in the two cohorts, the outcome 
of patients was very favorable with DFS rates of 97.6% 
and 91.5% and OS rates of 99.4% and 98.3% at 5 and 
10 years, respectively. At univariate analysis, only tumor 
grade and proliferation were significantly associated to 
DFS. In detail, DFS rates at 5 and 10 years were 94.4% 
and 84.9% vs 98.8% and 94.4% for patients with G3 vs 
G1-2 breast cancer (hazard ratio=2.53, 95% CI 1.42 to 
4.51, p=0.0017, Figure 1A), and 95.4% and 86.8% vs 
98.6% and 92.7% for patients with Ki67 ≥20% vs Ki67 
< 20% (hazard ratio=2.23, 95% CI 1.24 to 4, p=0.007, 
Figure 1B), respectively. Overall survival was unrelated 
to the other study variables. The type of relapse/event 
(local relapses, distant relapses and death without relapse) 
and their distribution in the two cohorts of patients are 
reported in Supplementary Table 3. Survival outcomes 
by histological grade, Ki67 and PgR are reported in 
Supplementary Table 4.
Not surprisingly given the distribution of baseline 
prognostic factors, the CT-cohort had a statistically 
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significant worse outcome compared to the HT-cohort 
with regard of DFS (hazard ratio=2.17, 95% CI 1.26 to 
3.75, p=0.005; Figure 2A) and OS (hazard ratio=4.32, 
95% CI 1.13 to 16.5, p=0.032; Figure 2B) at 5 years and 
10 years. Disease-free survival rates at 5 and 10 years 
were 95.6% (95% CI, 93.6%-97.8%) and 87.8% (95% CI, 
83.0%-92.8%) in the CT-cohort vs 98.5% (95% CI, 97.7% 
to 99.4%) and 94.1% (95% CI, 91.2%-97.2%) in the HT-
cohort, respectively (Table 2). Overall survival rates at 
5 and 10 years were 98.9% (95% CI, 97.8%-100%) and 
96.9% (95% CI, 94.3%-99.6%) in the CT-cohort and 
99.7% (95% CI, 99.3%-100%) and 99.4% (95% CI, 
98.5%-100%) in the HT-cohort, respectively (Table 3).
To evaluate in greater detail the impact of adjuvant 
treatment choice on clinical outcomes in a more 
homogeneous population, we analyzed survival outcome 
in a subgroup of 408 patients matched by propensity 
score (204 patients from the CT-cohort and 204 patients 
from the HT-cohort). The baseline characteristics of 
patients with luminal-like stage IA breast cancer matched 
by propensity score are reported in Supplementary Table 
5. The items matched were patient’s age, tumor size 
Table 1: Characteristics of tumors and patients at baseline
HT cohort
(N =842)
CT cohort
(N=380)
P-value
Age
Median (range) 61 (28-88) 50 (26-76) <0.001
<50 yrs 178 (21%) 179 (47%)
<0.001
≥50 yrs 664 (79%) 201 (53%)
Tumor size (N =1,191)
T1a 81(10%) 6 (2%)
<0.001T1b 317 (38%) 64 (18%)
T1c 428 (52%) 295 (81%)
Grade (N=1,170)
G1-2 719 (88%) 190 (53%)
<0.001
G3 95 (12%) 166 (47%)
Ki67 (N=1,049)
 <20% 553 (75%) 134 (44%)
<0.001
 ≥20% 188 (25%) 174 (56%)
 ≤14% 444 (60%) 100 (32%)
<0.001
 >14% 297 (40%) 208 (68%)
ER
Positive (≥1%) 842 (100%) 366 (96%) <0.001
Median (range) 90% (10-100%) 70% (0-80%) <0.001
PgR
Positive (≥1%) 770 (92%) 341 (90%) 0.24
High (≥20%) 686 (83%) 279 (75%) 0.002
Median (range) 70% (0-100%) 50% (0-100%) <0.001
Luminal (N=1040)
Luminal A 350 (48%) 70 (23%)
<0.001
Luminal B 384 (52%) 236 (77%)
Luminal A: ER+ (>1%), PgR high (≥20%), HER 2-negative and Ki67 ≤14%; Luminal B: ER+ (>1%); PgR low (<20%) 
and/or Ki67 >14%.
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category, histological grade, PgR expression, using a cut 
off of 20%, and Ki67 index, as a continuous variable. 
When variables were well balanced, neither DFS nor 
OS differed significantly between the two study cohorts 
(Figure 3A and 3B, respectively). We also explored the 
interaction between CT efficacy and Ki67 levels, and 
found it was not significant (data not shown); however, 
the number of events was too low to achieve sufficient 
statistical power.
Multivariate analyses
In a multivariable analysis, stratified by Oncologic 
Center, that included patient’s age (<50 years vs ≥50 
years), tumor size (T1a vs T1b vs T1c), histological 
grade (G1-G2 vs G3), tumor proliferation (Ki67 as a 
continuous variable), PgR levels (<20% vs ≥20%) and 
chemotherapy treatment (yes vs no), only histological 
grade had an independent prognostic value in predicting 
DFS (hazard ratio for G3 vs. G1-2 = 2.41, 95% CI 1.10 to 
5.28, p=0.028; Table 4).
DISCUSSION
Overall, our patients with luminal-like stage IA 
breast cancer had an excellent prognosis with survival 
rates at 5 and 10 years of 99% and 98%, respectively. Risk 
stratification, in our patients, was based on clinical and 
tumor parameters. As expected, given that the decision of 
proposing adjuvant CT was left to the physician, patients 
receiving this therapy were more likely to have worse 
prognostic characteristics (larger tumors with a higher 
proliferation index, higher tumor grade and lower ER and 
PgR expression levels) than patients receiving HT only. 
Among the clinical and immunohistochemical (IHC) 
parameters analyzed, only tumor grade was significantly 
related to DFS in our patients. Interestingly, despite the 
use of adjuvant CT, patients in the CT cohort still relapsed 
and their death rate was higher than that of the HT cohort. 
Moreover, when all the clinical and tumor features were 
matched by the propensity score, the addition of CT did 
not significantly improve either DFS or OS compared to 
HT alone.
Figure 1: Disease-free survival according to the main prognostic factors. (A) DFS for G1-2 vs G3 tumors and (B) DFS for 
tumors with Ki67 <20% vs tumors with Ki67 ≥20%.
Figure 2: DFS and OS for the CT-cohort vs the HT-cohort. (A) DFS and (B) OS for the CT-cohort vs the HT-cohort.
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Table 3: OS rates for HT vs CT-cohort
Cohort N. of patients N. of events OS rates at 5 
years (95% CI)
OS rates at 10 
years (95% CI)
Hazard Ratio
(95% CI)
CT vs HT
HT-cohort 842 3
99.7% 99.4%
4.32
(1.13-16.5) 
p=0.032*
(99.3%-100%) (98.5%-100%)
CT-cohort 380 9
98.9% 96.9%
(97.8%-100%) (94.3%-99.6%)
Whole population 1,222 12
99.4% 98.3%
(99.0%-99.8%) (96.9%-99.7%)
*univariate log rank test.
Table 2: DFS rates for HT-cohort vs CT-cohort
Cohort N. of patients N. of events DFS rates at 5 
years (95% CIs)
DFS rates at 10 
years (95% CI)
Hazard Ratio
(95% CI)
CT vs HT
HT-cohort 842 23
98.5% 94.1%
2.17 (1.26 - 3.75) 
p=0.005*
(97.7%-99.4%) (91.2%-97.2%)
CT-cohort 380 32
95.6% 87.8%
(93.6%-97.8%) (83%-92.8%)
Whole population 1,222 55
97.6% 91.5%
(96.6%-98.6%) (88.6%-94.4%)
*Univariate log rank test.
Figure 3: DFS for the CT-cohort vs the HT-cohort matched by propensity score. (A) DFS and (B) OS for the CT-cohort vs 
HT-cohort matched by propensity score with Ki67 as continuous variable.
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In the present study, patients’ age, tumor size, grade 
and proliferation, and median levels of ER and PgR 
expression played a critical role in disease management 
and guided physicians and patients in therapeutic decision-
making. Interestingly, however, we found that among 
all the clinical parameters and IHC-defined molecular 
biomarkers studied, only tumor grade correlated with DFS. 
Tumor differentiation is a well-established prognostic 
factor for breast cancer, and the grade score may affect 
the recommendation for CT in ER-positive tumors [18]. 
Our data and those of others [17], support the role of 
tumor grade in identifying, among patients with stage IA 
luminal breast cancer, women who may be at a higher risk 
of relapse, and may eventually need adjuvant CT.
The low rate of distant recurrence observed in the 
patients of the HT-cohort is consistent with previous 
reports [11, 12, 19-21] and is also in line with a risk of 
relapse of approximately 1% at 5 years reported by 
Sparano et al. in a similar patient population at a low risk 
based on clinicopathological features and receiving HT 
alone [17].
Not surprisingly, our patients in the CT-cohort had 
worse clinical and tumor characteristics and worse relapse 
and survival rates at 5 and 10 years compared to patients 
in the HT cohort. Of course, our results may reflect the 
increased baseline risk of patients in the CT cohort. 
However, the net benefit of adding CT to HT could not 
be evaluated in our study due to the lack of randomization 
and the retrospective nature of the analysis. In any event, 
when the patients’ baseline and tumor characteristics were 
matched by the propensity score, the addition of CT to HT 
did not further improve either DFS or OS. A recent meta-
analysis [22] demonstrated that new generation taxane-
plus-anthracycline chemotherapy regimens reduced the 
10-year risk of death from breast cancer by about a third. 
However, as relatively few patients in the trials included 
in the meta-analysis had small, well-differentiated luminal 
A-like tumors, no definitive conclusions can be drawn 
about the effects of CT on such low-risk tumors.
The predominant use of older taxane-free 
chemotherapy regimens in the present study (only 
16% of patients had received taxane and anthracycline 
regimens) and the relative endocrine resistance of these 
largely luminal B tumors may also have influenced 
patients’ outcome. Furthermore, data from recent 
neoadjuvant studies show that patients with ER-
positive tumors are less likely to achieve a complete 
response to chemotherapy [23-26] which suggests 
that ER positivity can also affect the proportional 
risk reduction seen with adjuvant chemotherapy. New 
generation taxane-plus-anthracycline chemotherapy 
regimens, longer duration of endocrine therapies, 
new molecules able to more effectively block the ER 
pathways or other critical cell checkpoints such as 
cyclin inhibitors may be required to further improve 
survival in this cohort of patients. In this context, it 
is feasible that genomic tests [21, 27, 28] will help to 
better stratify patients according to different risk of 
recurrence categories [29] and define the best adjuvant 
strategy.
Our study has several limitations. It is a multicenter 
retrospective evaluation, treatment allocation was not 
randomly assigned and pathology was not centralized. 
However, the homogeneity of the patient population, 
propensity score matching and multivariate analysis may 
counteract these limitations.
In conclusion, we confirm the overall excellent 
prognosis of stage I luminal breast cancer. We did not 
identify any molecular or clinical parameters other than 
tumor grade able to predict patient outcome. Notably, 
our study shows that low-risk ER-positive disease may 
be treated with HT alone and, because further risk 
reduction from adding CT, if any, will not be large in 
absolute terms, this therapeutic strategy should be 
weighed against its toxicity. Gene expression profiling 
may provide additional information to better select 
these patients in daily clinical practice. More studies 
are needed to improve outcome in patients with stage I 
luminal breast cancer who require CT because of a high-
risk score at genetic testing or a worse IHC molecular 
profile, because chemotherapy and 5 years HT may not 
be sufficient.
Table 4: Multivariate analyses with Cox regression model for DFS, stratified by oncologic center
Covariates Hazard Ratios 95% CI P value
Chemotherapy Yes vs No 0.66 0.28–1.57 0.35
Age ≥50 vs. <50 0.90 0.41–1.96 0.79
T category T1c vs T1b vs T1a 2.00 0.97–4.14 0.06
Grading G3 vs G1-2 2.50 1.14–5.48 0.022
Ki67 continuous variable 1.01 0.98–1.04 0.58
ER continuous variable 1.00 0.98–1.02 0.87
PgR continuous variable 1.00 0.99–1.01 0.95
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MATERIALS AND METHODS
Study population
We retrospectively collected the clinical and 
pathological data of early breast cancer patients who 
underwent surgery between 1996 and 2012 in four Italian 
oncologic centers (University of Naples “Federico II”, 
National Cancer Institute “G. Pascale”, Naples, AORN 
“A. Cardarelli” Hospital, Naples, and the “Santa Maria 
della Misericordia” University Hospital, Udine).
Pathologic data on tumor size (T), nodal status (N), 
histological grade (G), tumor proliferation measured by 
Ki67 labeling, estrogen receptor (ER), progesterone 
receptor (PgR) and HER2/neu status of each patient were 
retrieved. Breast tumors were staged according to the 
7th edition of the American Joint Committee on Cancer 
Staging (AJCC) Manual [7]. The histological grade 
was defined using the modified Bloom–Richardson–
Elston grading system [30]. The Ki67 percentage score 
was assessed using the MIB1 monoclonal antibody 
[31, 32]. Two thresholds for Ki67 positivity (14% and 
20%) were considered. HR expression was considered 
positive in case of ER and/or PgR immunostaining 
greater than 1% of invasive cells. ER and PgR were 
analyzed as described elsewhere [33]. PgR expression 
was considered high at a threshold of 20%, according 
to the St. Gallen Consensus [14]. HER2 receptor status 
was evaluated by IHC and expression level 3+ staining 
(DAKO Herceptest) was considered positive. In case of 
HER2 2+ staining, fluorescence in situ hybridization, 
chromogenic in situ hybridization, or silver in situ 
hybridization was performed to identify HER2 gene 
amplification. All tumors were classified as luminal-like 
breast cancers, with luminal-like A and B distinguished 
according to the St. Gallen Consensus [14]. In detail, 
tumors were classified as luminal A-like if ER positive 
(>1%), PgR high (≥20%), HER2 negative and Ki67 low 
(≤14%) or luminal B-like if ER positive (>1%) and PgR 
low (<20%) and/or Ki67 high (>14%). Patients with a 
diagnosis of breast carcinoma in situ (Tis), or of invasive 
carcinoma with no invasive lesion measuring more than 
1 mm (T1mic), or a follow-up shorter than 1 year were 
excluded from the analysis. Overall, 1,222 patients with 
luminal-like stage IA breast cancer were retrospectively 
identified: 380 patients received CT and HT (CT-cohort) 
and 842 HT only (HT-cohort) as adjuvant therapy. All 
patients received postoperative local irradiation if 
indicated according to current guidelines and patient 
comorbidities.
This study was approved by the Ethic Committees 
of each participant center (IRB protocol number for 
Coordinating Center: 178/15). Due to the retrospective 
nature of the study, written informed consent was waived, 
according to Italian Law.
Statistical analyses
Patients were divided into two cohorts according to 
the adjuvant systemic treatment administered: HT alone 
(HT-cohort) and CT followed by HT (CT-cohort). The χ2 
test was used to assess differences between the groups in 
the distribution of categorical prognostic variables [34]. 
Disease-free survival was defined as the time from surgery 
to the date of the first event, including local or distant 
recurrence or death, whichever occurred first. For survivors, 
DFS was censored at the date of the last available follow-up. 
Overall survival was defined as the time from surgery until 
the date of death (from any cause) with censoring at the date 
of last available follow-up. The DFS and OS distributions 
were estimated using the Kaplan-Meier method [35]. The 
log-rank test was used to assess the difference in survival 
distribution between the groups [36]. Multivariate Cox 
proportional hazard regression analysis [37] was used 
to assess the independent prognostic significance of 
the various clinical and pathological characteristics on 
DFS or OS. To reduce biases related to the non-random 
assignment of the compared treatment strategies (CT 
cohort vs HT cohort), we applied the propensity score 
methodology [38-40]. With this method, the relationship 
between therapy and outcome is adjusted for the likelihood 
that a patient has of receiving that treatment, given her 
baseline characteristics. In detail, the propensity score 
(chance of receiving chemotherapy) was estimated by 
a logistic regression model that included, as dependent 
variable, the receipt of chemotherapy and, as covariates, 
factors that are likely to influence the decision whether 
or not to administer chemotherapy (age, tumor category, 
grading, PgR expression category and Ki67 value). Only 
subjects with overlapping values of the propensity score 
were included in the matched groups, with a 1:1 matching 
between the two study cohorts, allowing a 0.2 caliper (i.e. 
the maximum tolerated difference in the propensity score 
between matched subjects). After matching, patients of the 
2 groups had a similar distribution of propensity scores, 
and consequently the 2 matched groups are similar in terms 
of age, T, grading, PgR and Ki67, whereas these factors 
differed greatly between the two unmatched groups.
Statistical analyses were performed with S-PLUS 
6.0 Professional (release 1; Insightful Corporation, 
Seattle, WA, USA) and IBM SPSS Statistics (release 
24.0.0.0). Propensity score analysis was performed using 
Propensity Score Matching for SPSS, Version 3.0.4 
(Thoemmes, F. 2012. Propensity score matching in SPSS. 
arXiv:1201.6385).
Abbreviations
BC: breast cancer; CI: confidence interval; CT: 
chemotherapy; DFS: disease-free survival; ER: estrogen 
receptor; G: tumor grading; HR: hormone receptors; HT: 
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hormone therapy; N: lymph nodal involvement; OS: 
overall survival; PGR: progesterone receptor; T: tumor 
size.
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